Effect of medium cut‐off membranes on Pentosidine and N‐(carboxymethyl) lysine levels in uncontrolled diabetic hemodialysis patients

IF 1.5 4区医学 Q3 HEMATOLOGY

Therapeutic Apheresis and Dialysis Pub Date : 2024-04-04 DOI:10.1111/1744-9987.14126

Neriman Sıla Koç, Hasan Yeter, Tolga Yıldırım, Yunus Erdem, Rahmi Yılmaz

{"title":"Effect of medium cut‐off membranes on Pentosidine and N‐(carboxymethyl) lysine levels in uncontrolled diabetic hemodialysis patients","authors":"Neriman Sıla Koç, Hasan Yeter, Tolga Yıldırım, Yunus Erdem, Rahmi Yılmaz","doi":"10.1111/1744-9987.14126","DOIUrl":null,"url":null,"abstract":"IntroductionPatients on hemodialysis, especially with diabetes, face elevated cardiovascular events. A major contributor to complications associated with diabetes is advanced glycation end products (AGEs). Removing these compounds is challenging in traditional hemodialysis. Medium‐cut‐off (MCO) membranes potentially remove toxins without significant albumin loss. This study explored how MCO membranes impact AGEs levels in uncontrolled diabetic patients undergoing hemodialysis.MethodsSixteen patients received MCO membrane dialysis, while others used high‐flux (HF) membranes. After 12 sessions, the dialyzers were switched, totaling 24 sessions. Blood samples at trial initiation (T0), session 12 (T1) and session 24 (T2) tested for CML, Pentosidine, laboratory parameters.ResultsSwitching dialyzers showed increased albumin with MCO‐to‐HF and decreased with HF‐to‐MCO, albeit nonsignificant (p = 0.5/p = 0.1). Patients on MCO had lower albumin levels than HF (p = 0.03/p = 0.6, respectively). Hemodialysis with MCO demonstrated lower levels of CML/Pentosidine compared to HF (p = 0.09/p = 0.9 for CML; p = 0.04/p = 0.3 for Pentosidine). Transitioning to HF led to elevated levels (p = 0.4/p = 0.09 for CML; p = 0.3/p = 0.07 for Pentosidine).ConclusionMCO dialysis in diabetic individuals notably reduces AGE levels.","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"18 1","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.14126","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

IntroductionPatients on hemodialysis, especially with diabetes, face elevated cardiovascular events. A major contributor to complications associated with diabetes is advanced glycation end products (AGEs). Removing these compounds is challenging in traditional hemodialysis. Medium‐cut‐off (MCO) membranes potentially remove toxins without significant albumin loss. This study explored how MCO membranes impact AGEs levels in uncontrolled diabetic patients undergoing hemodialysis.MethodsSixteen patients received MCO membrane dialysis, while others used high‐flux (HF) membranes. After 12 sessions, the dialyzers were switched, totaling 24 sessions. Blood samples at trial initiation (T0), session 12 (T1) and session 24 (T2) tested for CML, Pentosidine, laboratory parameters.ResultsSwitching dialyzers showed increased albumin with MCO‐to‐HF and decreased with HF‐to‐MCO, albeit nonsignificant (p = 0.5/p = 0.1). Patients on MCO had lower albumin levels than HF (p = 0.03/p = 0.6, respectively). Hemodialysis with MCO demonstrated lower levels of CML/Pentosidine compared to HF (p = 0.09/p = 0.9 for CML; p = 0.04/p = 0.3 for Pentosidine). Transitioning to HF led to elevated levels (p = 0.4/p = 0.09 for CML; p = 0.3/p = 0.07 for Pentosidine).ConclusionMCO dialysis in diabetic individuals notably reduces AGE levels.

查看原文本刊更多论文

介质截流膜对不受控制的糖尿病血液透析患者体内喷托苷和 N-（羧甲基）赖氨酸水平的影响

导言血液透析患者，尤其是糖尿病患者，面临着心血管事件的增加。导致糖尿病并发症的一个主要因素是高级糖化终产物（AGEs）。在传统的血液透析中，清除这些化合物是一项挑战。中截留（MCO）膜有可能在不损失大量白蛋白的情况下清除毒素。本研究探讨了 MCO 膜如何影响接受血液透析的未控制糖尿病患者体内的 AGEs 水平。12次透析后，更换透析器，共进行了24次透析。在试验开始时（T0）、第 12 次（T1）和第 24 次（T2）采集的血样检测了 CML、喷托苷和实验室参数。MCO 患者的白蛋白水平低于 HF（分别为 p = 0.03/p = 0.6）。与高频透析相比，接受 MCO 血液透析的患者白蛋白/喷托西汀水平较低（白蛋白 p = 0.09/p = 0.9；喷托西汀 p = 0.04/p = 0.3）。转为高频透析后，AGE 水平升高（CML 的 p = 0.4/p = 0.09；喷托西啶的 p = 0.3/p = 0.07）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.